

A Rare Presentation of Endometrial Cancer recurrence with Scapular metastasis: A Case Report and Review of the Literature

Nagandla Kavitha¹ , Noor Azura Noor Mohamad¹ , Nirmala Kampam³ , Mohamad Nasir Shafiee³



¹Department of Obstetrics & Gynecology, International Medical University, Clinical Campus

²Department of Obstetrics & Gynecology, Universiti Teknologi MARA

³Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia

Correspondence to: Nagandla Kavitha; email: kavitha_nagandla@imu.edu.my

Received: 10 Jul 2021; Revised: 14 Nov 2021; Accepted: 26 Nov 2021; Available online: ***

Abstract

Bone metastasis from endometrial cancer is rare. Most of the early stage endometrial cancers with endometrioid histology are confined to the uterus at the time of diagnosis and confer a good prognosis. Endometrial metastases to the bone are generally restricted to the axial skeleton, including the pelvis and thoracolumbar vertebrae. Skeletal metastases in the appendicular skeleton such as scapula, clavicle and extremities to tibia, and tarsus are rarely reported. We present the case of a 50-year-old woman with diagnosis of endometrioid adenocarcinoma of the endometrium, FIGO stage IB, grade 2, with lympho-vascular space invasion who developed recurrence within 10 months with bone metastasis to left scapula and extrasosseous soft tissue

mass over left shoulder. There are very few cases reported in literature of scapular metastases in an early-stage endometrial carcinoma. We discuss evaluation, treatment options, overall survival rates and provide a literature review of prior published reports.

Keywords: Endometrial Carcinoma, Recurrence, Bone metastasis, Scapula

Conflict of interest: None

Funding: None.

© 2022 Author. This work is licensed under the Creative Commons Attribution 4.0 International License.

Introduction

Endometrial cancer is among the most common gynaecologic malignancy accounting for 6% of all cancers in women globally (1). Majority of cases are diagnosed in early stage, endometrioid subtypes with favourable prognosis. The risk of recurrence is 10-15% and majority of recurrence are estimated to occur in three years from primary diagnosis (2). The most common sites of recurrence include pelvic, para-aortic lymph nodes, vagina, peritoneum, and lungs. These are considered as typical sites of recurrence in 80-90% of cases (3). However, the atypical sites of recurrence include bones, brain, intra-abdominal organs, abdominal

wall, and muscle (4). The prevalence of osseous metastases in endometrial carcinoma ranges from 4 to 7% (5), whereas the muscular and soft tissue metastases is 2 to 6% (6). Due to its atypical site, we report this case of endometrioid adenocarcinoma of the endometrium with bone metastasis to scapula and extrasosseous soft tissue mass. As to date, there is only one case that has been reported in the literature (7).

Case report

A 50-year-old woman para 3 presented with abnormal uterine bleeding and endometrial sampling revealed a complex endometrial hyperplasia with atypia.

Computed tomography of thorax, abdomen, and pelvis (CT TAP) was suggestive of endometrial mass with no locoregional extension. Following that, she underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy with pelvic and para-aortic lymphadenectomy. The histopathological examination showed moderately differentiated endometrioid adenocarcinoma with tumour invading more than half of the myometrium, FIGO stage 1B with lymphovascular space invasion. According to ESMO-ESGO-ESTRO consensus on endometrial cancer 2016, the tumour was in the category of high intermediate-risk hence it was decided by a multidisciplinary team of gynecologic surgeons, pathologists, and oncologists to proceed with adjuvant radiotherapy. The patient received brachytherapy to the vaginal cuff with total dose of 24 Gray (Gy) (4 fractions of 6 Gy) which was completed 4 weeks following surgery. However, five months after the completion of radiotherapy, she presented with left shoulder swelling and pain and limited restricted of movements. A magnetic resonance imaging (MRI) of left shoulder revealed a 3x5x6 cm bony mass, suggestive of metastases (Figure 1).



Figure 1. A magnetic resonance imaging (MRI) of left shoulder revealing a 3x5x6 cm bony mass, suggestive of metastases

Additional computed tomography showed an ill-defined lytic lesion at the left scapula, multiple lung metastasis, enlarged left supraclavicular, left axillary and abdominal lymph nodes. Positron emission tomography (PET)/CT of the whole body demonstrated an ill-defined lytic lesion with extensive soft tissue component seen in superior aspect of the left scapula with increased FDG

uptake (SUV max 15.9) and multiple liver metastasis (Figure 2).




Figure 2. Positron emission tomography (PET)/CT of the whole body demonstrating an ill-defined lytic lesion with extensive soft tissue component seen in superior aspect of the left scapula with increased FDG uptake (SUV max 15.9) and multiple liver metastasis (Figure 2).

There were also hypermetabolic paraaortic, aortocaval lymph nodes and left supraclavicular and axillary lymph nodes. Based on the clinical, radiological, and histological examination via core biopsy, a diagnosis of recurrent endometrioid adenocarcinoma of endometrium with nodal recurrence and scapular metastasis was confirmed. She was reviewed by medical oncologist to receive palliative chemoradiation. She underwent 5 fractions of 20 Gy radiation therapy at her left shoulder and started on chemotherapy of carboplatin AUC 4 and paclitaxel 175 mg/m² for six cycles. Upon follow-up, her neuropathic pain was much improved, and she was scheduled for a regular, 3-monthly follow-up. At 6 months, the shoulder swelling resolved, with complete range of movement. A repeat CT revealed a complete remission of distant metastasis.

Discussion

This case report describes an atypical site of metastasis of endometrioid adenocarcinoma of endometrium. A review of literature revealed only one reported case so far of endometrial carcinoma metastatic to the scapula wherein bony metastases was the primary presentation (7). This case adds to literature of bone metastases to the scapula at early stage with endometrioid histology with moderately differentiated tumour.

The overall incidence of bony metastasis is 0–15% of all metastatic endometrial cancers (8). The most common sites of bony metastases include the axial skeleton (vertebrae and pelvis) in the presence of advanced disease and poorly differentiated tumors (9). Recurrent endometrial carcinoma with metastatic lesions are found predominantly in the lymph nodes, omentum, lungs, and liver (10). The mode of spread is either by direct invasion or via the lympho-vascular pathway (11). The mechanism of spread is thought to be related to the tumor behavior, vascular supply, immune system, and bone environment (12). Albaredo *et al* postulated that the venous backflow in the tumour spread that can result in greater propensity to lower extremity involvement (13). It has been identified that one of the important factors for skeletal involvement is the histological type whereby high-grade lesions have been associated with an increase in bony metastasis (14). This is further supported by recent study by Hong L *et al*, that serous histology is strongly associated with developing bone metastasis (15). Abdul-Karim *et al*. determined that bone metastasis was related to moderately or poorly differentiated EC (16). Although it is rare, there are few reports of bone metastases in well-differentiated endometrial carcinoma (17).

In our case, the patient presented with symptoms of bone pain which prompted further evaluation. Presence of soft tissue mass in the MRI of shoulder prompted further assessment with CT TAP which revealed lytic tissue of left scapula. PET/CT of whole body provides an added advantage of assisting in the differentiating between benign and malignant disease (18). It is essential to ascertain the pathological diagnosis of any bony lesions by a biopsy. A percutaneous method of biopsy via fine needle aspiration and core biopsy has been proven

effective for pathological evaluation of bone lesions especially in the presence of soft tissue component as illustrated by this case (19).

Currently there are no recommendations for screening for bone metastases upon initial diagnosis of endometrial carcinoma or as post-treatment surveillance. However, targeted screening can be considered for development of bone metastasis in the presence of serous and type II endometrial cancer histology. Furthermore, PET/CT should be considered in symptomatic patients in type I histology as the diagnosis can be missed by conventional CT imaging (14). Most patients present with pain (81%) or fracture (9.5%) at the time of diagnosis of bone metastasis (20). There is no protocol or standard recommendation in the management of bone metastasis. Based on the literature, the most common treatment includes multimodality approach such as surgical excision of the lesion, site-directed radiation therapy, and chemotherapy (21). Treatment modality depends on the number of sites of metastasis, concomitant extraosseous metastasis, response to previous therapy and performance status of the patient (20). Our patient received directed radiation followed by chemotherapy. It has been postulated that the indication for systemic chemotherapy is an extrapolation from the management of recurrent endometrial carcinoma with locoregional metastasis where a combination of paclitaxel and carboplatin is the standard of practice (11). There are case reports on the benefit of zoledronic acid for bone metastasis of endometrial cancer. The evidence stemmed from other solid tumors such as prostate and breast, bisphosphonates could be considered as the treatment modality (22).

Based on the case series by Yoon *et al.*, the median overall survival (OS) and progression free survival following bone metastasis was 33 months (range 9–57 months) and 15 months (range 12–17 months), respectively (20). It has been determined that the patients with bone metastasis at recurrence had significantly longer OS as opposed to those patients with bone metastasis at the diagnosis of endometrial carcinoma (36 vs. 13 months; $P = 0.042$) (20). This is further supported in series by Uccella *et al* highlighting

that isolated bone metastasis with no extraosseous spread is associated with longer survival (26 vs. 6 months; $P = 0.008$) (10). In our patient, bone metastasis occurred 10 months after the primary diagnosis. There is also extraosseous spread at lung and caval lymph nodes. At this point we are unable to determine the survival chances of this patient and only time will answer this question.

Molecular signature and clinical applications

With the new genomic era, there has been a call for integration of molecular features in the risk stratification of endometrial carcinomas (23). This will contribute towards better assessment of biological behavior of individual patient's treatment decisions and outcomes (24). So far, the most comprehensive molecular study of endometrial carcinoma has emerged from the data from The Cancer Genome Atlas (TCGA) project, which has classified the endometrial cancer molecular information into four groups - *POLE* ultramutated, MSI hypermutated, copy-number (CN) low, and CN high which all correlates with the disease progression and overall survival rate (25,26).

Endometrial cancers with *POLE* mutations are observed in younger, thinner women who show favorable prognosis regardless of grade, myometrial invasion and LVSI status (27). It is observed that patients belonging to the *POLE* and the MSI subgroups emerged as tumors with much better survival outcomes as compared to comparison to the p53 mutant group and the NSMP group which are associated with poor prognosis and early recurrence, despite an endometrioid histology (28). It is plausible that our patient would have belonged to p53 mutant group or the NSMP group of molecular characterization that would have possibly contributed to aggressive disease progression. However, integrating molecular classification as standard care will require more prospective clinical trial determining the survival rates, quality of life and health economic implications at local context (29) Currently, several different targeted therapies are undergoing clinical evaluation. In particular, EGFR, human epidermal growth factor receptor-2 (HER2), mTOR and VEGFR inhibitors that have been tested in phase I and II trials, with modest

response rates (30). The present literature provides some promising findings with PI3Kinase, mTOR and angiogenesis inhibitors (31,32). However more evidence is required in this area with studies which should be biomarkers driven.

Conclusion

Scapular metastasis in early stage of endometrial carcinoma with endometrioid histology and moderately differentiated tumor is a rare entity. Till date, only one such case is reported with advanced stage. Although bone metastasis is a rare occurrence in endometrial carcinoma especially in early stage, due attention to bone pain or joint swelling will assist in timely diagnosis and targeted treatment that will enable good palliation and prolong survival. Given the increasing incidence of endometrial cancer and the overall cost implications, there is a role of integrating molecular information on the hysterectomy specimens as value added tool for better prognostication of these tumors. Evidences are promising for targeted therapy but need validation with clinical trials essentially biomarker driven.

Conflict of Interest

The authors have no conflicts of interest to declare.

Consent

Written informed consent was obtained from the patient described for publication of the images and case detail.

Financial Disclosure

The authors declared that this study has received no financial support.

References

1. Kehoe SM, Zivanovic O, Ferguson SE, et al. Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. *Gynecol Oncol.* 2010; 117:229–33.
2. Creasman, WT, Odicino, P. Maisonneuve U, et al. Carcinoma of the corpus uteri. *J. Epidemiol. Biostat.* 2001; 6:47–86.
3. Kumar, V., Abbas, A. K., & Aster, J. C. The female genital tract. *Robbins Basic Pathology.* 10th ed., Elsevier - Health Sciences Division, 2017

4. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium. A clinical and histopathological study of 379 patients. *Gynecol Oncol.* 1984; 17:85–103.
5. Sohaib SA, Houghton SL, Rexnek RH, et al. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. *Clin Radiol.* 2007;62:28–34.
6. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage 1 carcinoma of endometrium. *Gynecol Oncol.* 2004; 95:593–596.
7. Turner S, Schiano M, Jubelirer S, Campbell J. Endometrial carcinoma diagnosed by scapular biopsy: A case report. *Gynecol Oncol Case Rep.* 2011;1(1):10-11
8. Neto, A. G., D. Gupta, R. Broaddus, et al. Endometrial endometrioid adenocarcinoma in a premenopausal woman presenting with metastasis to bone: a case report and review of the literature. *Int. J. Gynecol. Pathol.* 2002; 21: 281– 284
9. Chan, J. K Kapp D.S, Cheung M. K, et al. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. *Am. J. Obstet. Gynecol.* 2008;198: 216 216.
10. Uccella S, Morris JM, Bakkum-Gamez JN, et al. Bone metastases in endometrial cancer: Report on 19 patients and review of the medical literature. *Gynecol Oncol.* 2013; 130:474–82
11. Devdas SK, Digumarti L, Digumarti R, et al. Isolated humeral recurrence in endometrial carcinoma [published correction appears in *Indian J Med Paediatr Oncol.* 2016; 37(4):320.
12. Ishibashi, M., R. Fujiwaki, I. Nakayama, et al. Endometrial carcinosarcoma presenting as a tibial metastasis. *Int. J. Clin. Oncol* 2007; 12:305–308.
13. Albareda J, Herrera M, Lopez Salva A, et al. Sacral metastasis in a patient with endometrial cancer: case report and review of the literature. *Gynecol Oncol* 2008; 111:583–8.
14. Hong, L., Cristiano, L., Peters, E, et al. Detection of bone metastases in uterine cancer: How common are they and should PET/CT be the standard for diagnosis? *Gynecologic oncology reports*, 2021;35 100698.
15. Nguyen M.L.T, Christopher J. Tarah L. et al. Grade 1 Endometrioid Endometrial Carcinoma Presenting with Pelvic Bone Metastasis: A Case Report and Review of the Literature", *Case Reports in Obstetrics and Gynecology*, 2013; 807205-807205
16. Abdul-Karim F.W., Kida M., Wentz W.B. Bone metastasis from gynecologic carcinomas: a clinicopathologic study. *Gynecol. Oncol.* 1990;39(2):108–114
17. Lunardi P, Vidal F, Accadbled, F, et al. Bilateral femur metastases in low-grade endometrial carcinoma. *Clinical case reports*, 2015; 3(7), 582–586.
18. Hicks R.J., Ware R.E., Lau E.U. PET/CT: will it change the way that we use CT in cancer imaging? *Cancer Imaging.* 2006;31(6):S52–S62.
19. Omura M.C., Motamedi K., UyBico S., et al. Revisiting CT-guided percutaneous core needle biopsy of musculoskeletal lesions: contributors to biopsy success. *AJR Am. J. Roentgenol.* 2011;197(2):457–461
20. Yoon A, Choi CH, Kim TH, et al. Bone metastasis in primary endometrial carcinoma: Features, outcomes, and predictors. *Int J Gynecol Cancer.* 2014; 24:107–12
21. Shigemitsu, N. Furukawa, N. Koike, et al, "Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic acid: a case report and review of the literature," *Case Reports in Oncology*, 2010; 3: 471–476.
22. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. *Ann Oncol.* 2012; 23:2271–7
23. Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. *Gynecol Oncol Res Pract.* 2016; 3:14.
24. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. *Lancet Oncol.* 2014;15(7): 268–78.
25. Bendifallah S, Darai E, Ballester M. Predictive modeling: a new paradigm for managing endometrial cancer. *Ann Surg Oncol.* 2016;23(3):975–88
26. Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol.* 1983;15(1):10–7.
27. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013;24(6):33–8.
28. Leon-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. *J Pathol* 2020;250:312–22.
29. Mcconechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. *Mod Pathol.* 2014;27(1):128–34
30. Kamat AA, Merritt WM, Coffey D et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. *Clin Cancer Res* 2007;13: 7487–7495.
31. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. *Lancet Oncol* 2012; 13: e353–e361.
32. Dedes KJ, Wetterskog D, Ashworth A et al. Emerging therapeutic targets in endometrial cancer. *Nat Rev Clin Oncol* 2011; 8: 261–271.